Who is sponsoring NCT03584659?

NCT03584659 is sponsored by Rigshospitalet, Denmark.

What drugs are being tested in NCT03584659?

Interventions in NCT03584659: Electronic patient-reported outcomes.

What condition does NCT03584659 study?

NCT03584659 studies Bladder Cancer, Urothelial Carcinoma.

Is NCT03584659 still recruiting?

NCT03584659 is currently completed. Last updated 25 October 2022.

Last reviewed 2022-10-25 · How we verify

NCT03584659: iBLAD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Patient-reported Outcomes in Bladder Cancer

Completed NA Last updated 25 October 2022

What this trial tests

NA trial testing Electronic patient-reported outcomes in Bladder Cancer in 230 participants. Completed in 31 March 2022.

Timeline

21 January 2019

Primary endpoint
30 September 2021

31 March 2022

Quick facts

Lead sponsor	Rigshospitalet, Denmark
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	230
Start date	21 January 2019
Primary completion	30 September 2021
Estimated completion	31 March 2022
Sites	4 locations across Denmark

Drugs / interventions tested

Electronic patient-reported outcomes

Conditions studied

Bladder Cancer — all drugs for Bladder Cancer →
Urothelial Carcinoma — all drugs for Urothelial Carcinoma →

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, any sex, with Bladder Cancer or Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Electronic reporting of patient-reported outcomes with alert algorithm will be tested in a randomized trial in bladder cancer patients undergoing chemo- or immunotherapy. The clinical endpoints will be: * Quality of life * Completion of treatment * Hospital admission * Dose reductions * Survival

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy - a feasibility study.
Taarnhøj GA, Lindberg H, Dohn LH, Omland LH, et al · · 2020 · cited 27× · PMID 32653005 · DOI 10.1186/s12955-020-01480-3
Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy.
Taarnhøj GA, Lindberg H, Johansen C, Pappot H. · · 2019 · cited 20× · PMID 31440865 · DOI 10.1186/s41687-019-0141-2
Patient-Reported Outcomes, Health-Related Quality of Life, and Clinical Outcomes for Urothelial Cancer Patients Receiving Chemo- or Immunotherapy: A Real-Life Experience.
Taarnhøj GA, Lindberg H, Johansen C, Pappot H. · · 2021 · cited 14× · PMID 33923176 · DOI 10.3390/jcm10091852
The iBLAD study: patient-reported outcomes in bladder cancer during oncological treatment: a multicenter national randomized controlled trial.
Taarnhøj GA, Johansen C, Carus A, Dahlrot RH, et al · · 2023 · cited 8× · PMID 37812306 · DOI 10.1186/s41687-023-00640-5

Verify or expand the search:

Other recruiting trials for Bladder Cancer

Currently open trials in the same condition.

NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03584659 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
Last refreshed: 25 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03584659.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing